Clinical Decision Support

Clinical Decision Support Documents

Description

Generate professional clinical decision support (CDS) documents for pharmaceutical companies, clinical researchers, and medical decision-makers. This skill specializes in analytical, evidence-based documents that inform treatment strategies and drug development:

1. Patient Cohort Analysis - Biomarker-stratified group analyses with statistical outcome comparisons 2. Treatment Recommendation Reports - Evidence-based clinical guidelines with GRADE grading and decision algorithms

All documents are generated as publication-ready LaTeX/PDF files optimized for pharmaceutical research, regulatory submissions, and clinical guideline development.

Note: For individual patient treatment plans at the bedside, use the treatment-plans skill instead. This skill focuses on group-level analyses and evidence synthesis for pharmaceutical/research settings.

Writing Style: For publication-ready documents targeting medical journals, consult the venue-templates skill's medical_journal_styles.md for guidance on structured abstracts, evidence language, and CONSORT/STROBE compliance.

Capabilities

Document Types

Patient Cohort Analysis

• Biomarker-based patient stratification (molecular subtypes, gene expression, IHC)
• Molecular subtype classification (e.g., GBM mesenchymal-immune-active vs proneural, breast cancer subtypes)
• Outcome metrics with statistical analysis (OS, PFS, ORR, DOR, DCR)
• Statistical comparisons between subgroups (hazard ratios, p-values, 95% CI)
• Survival analysis with Kaplan-Meier curves and log-rank tests
• Efficacy tables and waterfall plots
• Comparative effectiveness analyses
• Pharmaceutical cohort reporting (trial subgroups, real-world evidence)

Treatment Recommendation Reports

• Evidence-based treatment guidelines for specific disease states
• Strength of recommendation grading (GRADE system: 1A, 1B, 2A, 2B, 2C)
• Quality of evidence assessment (high, moderate, low, very low)
• Treatment algorithm flowcharts with TikZ diagrams
• Line-of-therapy sequencing based on biomarkers
• Decision pathways with clinical and molecular criteria
• Pharmaceutical strategy documents
• Clinical guideline development for medical societies

Clinical Features

• Biomarker Integration: Genomic alterations (mutations, CNV, fusions), gene expression signatures, IHC markers, PD-L1 scoring
• Statistical Analysis: Hazard ratios, p-values, confidence intervals, survival curves, Cox regression, log-rank tests
• Evidence Grading: GRADE system (1A/1B/2A/2B/2C), Oxford CEBM levels, quality of evidence assessment
• Clinical Terminology: SNOMED-CT, LOINC, proper medical nomenclature, trial nomenclature
• Regulatory Compliance: HIPAA de-identification, confidentiality headers, ICH-GCP alignment
• Professional Formatting: Compact 0.5in margins, color-coded recommendations, publication-ready, suitable for regulatory submissions

Pharmaceutical and Research Use Cases

This skill is specifically designed for pharmaceutical and clinical research applications:

Drug Development

• Phase 2/3 Trial Analyses: Biomarker-stratified efficacy and safety analyses
• Subgroup Analyses: Forest plots showing treatment effects across patient subgroups
• Companion Diagnostic Development: Linking biomarkers to drug response
• Regulatory Submissions: IND/NDA documentation with evidence summaries

Medical Affairs

• KOL Education Materials: Evidence-based treatment algorithms for thought leaders
• Medical Strategy Documents: Competitive landscape and positioning strategies
• Advisory Board Materials: Cohort analyses and treatment recommendation frameworks
• Publication Planning: Manuscript-ready analyses for peer-reviewed journals

Clinical Guidelines

• Guideline Development: Evidence synthesis with GRADE methodology for specialty societies
• Consensus Recommendations: Multi-stakeholder treatment algorithm development
• Practice Standards: Biomarker-based treatment selection criteria
• Quality Measures: Evidence-based performance metrics

Real-World Evidence

• RWE Cohort Studies: Retrospective analyses of patient cohorts from EMR data
• Comparative Effectiveness: Head-to-head treatment comparisons in real-world settings
• Outcomes Research: Long-term survival and safety in clinical practice
• Health Economics: Cost-effectiveness analyses by biomarker subgroup

When to Use

Use this skill when you need to:

• Analyze patient cohorts stratified by biomarkers, molecular subtypes, or clinical characteristics
• Generate treatment recommendation reports with evidence grading for clinical guidelines or pharmaceutical strategies
• Compare outcomes between patient subgroups with statistical analysis (survival, response rates, hazard ratios)
• Produce pharmaceutical research documents for drug development, clinical trials, or regulatory submissions
• Develop clinical practice guidelines with GRADE evidence grading and decision algorithms
• Document biomarker-guided therapy selection at the population level (not individual patients)
• Synthesize evidence from multiple trials or real-world data sources
• Create clinical decision algorithms with flowcharts for treatment sequencing

Do NOT use this skill for:

• Individual patient treatment plans (use treatment-plans skill)
• Bedside clinical care documentation (use treatment-plans skill)
• Simple patient-specific treatment protocols (use treatment-plans skill)

Visual Enhancement with Scientific Schematics

⚠️ MANDATORY: Every clinical decision support document MUST include at least 1-2 AI-generated figures using the scientific-schematics skill.

This is not optional. Clinical decision documents require clear visual algorithms. Before finalizing any document: 1. Generate at minimum ONE schematic or diagram (e.g., clinical decision algorithm, treatment pathway, or biomarker stratification tree) 2. For cohort analyses: include patient flow diagram 3. For treatment recommendations: include decision flowchart

How to generate figures:

• Use the scientific-schematics skill to generate AI-powered publication-quality diagrams
• Simply describe your desired diagram in natural language
• Nano Banana Pro will automatically generate, review, and refine the schematic

How to generate schematics:

python scripts/generate_schematic.py "your diagram description" -o figures/output.png

The AI will automatically:

• Create publication-quality images with proper formatting
• Review and refine through multiple iterations
• Ensure accessibility (colorblind-friendly, high contrast)
• Save outputs in the figures/ directory

When to add schematics:

• Clinical decision algorithm flowcharts
• Treatment pathway diagrams
• Biomarker stratification trees
• Patient cohort flow diagrams (CONSORT-style)
• Survival curve visualizations
• Molecular mechanism diagrams
• Any complex concept that benefits from visualization

For detailed guidance on creating schematics, refer to the scientific-schematics skill documentation.

---

Document Structure

CRITICAL REQUIREMENT: All clinical decision support documents MUST begin with a complete executive summary on page 1 that spans the entire first page before any table of contents or detailed sections.

Page 1 Executive Summary Structure

The first page of every CDS document should contain ONLY the executive summary with the following components:

Required Elements (all on page 1): 1. Document Title and Type

• Main title (e.g., "Biomarker-Stratified Cohort Analysis" or "Evidence-Based Treatment Recommendations")
• Subtitle with disease state and focus

2. Report Information Box (using colored tcolorbox)

• Document type and purpose
• Date of analysis/report
• Disease state and patient population
• Author/institution (if applicable)
• Analysis framework or methodology

3. Key Findings Boxes (3-5 colored boxes using tcolorbox)

• Primary Results (blue box): Main efficacy/outcome findings
• Biomarker Insights (green box): Key molecular subtype findings
• Clinical Implications (yellow/orange box): Actionable treatment implications
• Statistical Summary (gray box): Hazard ratios, p-values, key statistics
• Safety Highlights (red box, if applicable): Critical adverse events or warnings

Visual Requirements:

• Use \thispagestyle{empty} to remove page numbers from page 1
• All content must fit on page 1 (before \newpage)
• Use colored tcolorbox environments with different colors for visual hierarchy
• Boxes should be scannable and highlight most critical information
• Use bullet points, not narrative paragraphs
• End page 1 with \newpage before table of contents or detailed sections

Example First Page LaTeX Structure:

\maketitle
\thispagestyle{empty}

% Report Information Box
\begin{tcolorbox}[colback=blue!5!white, colframe=blue!75!black, title=Report Information]
\textbf{Document Type:} Patient Cohort Analysis\\
\textbf{Disease State:} HER2-Positive Metastatic Breast Cancer\\
\textbf{Analysis Date:} \today\\
\textbf{Population:} 60 patients, biomarker-stratified by HR status
\end{tcolorbox}

\vspace{0.3cm}

% Key Finding #1: Primary Results
\begin{tcolorbox}[colback=blue!5!white, colframe=blue!75!black, title=Primary Efficacy Results]
\begin{itemize}
    \item Overall ORR: 72\% (95\% CI: 59-83\%)
    \item Median PFS: 18.5 months (95\% CI: 14.2-22.8)
    \item Median OS: 35.2 months (95\% CI: 28.1-NR)
\end{itemize}
\end{tcolorbox}

\vspace{0.3cm}

% Key Finding #2: Biomarker Insights
\begin{tcolorbox}[colback=green!5!white, colframe=green!75!black, title=Biomarker Stratification Findings]
\begin{itemize}
    \item HR+/HER2+: ORR 68\%, median PFS 16.2 months
    \item HR-/HER2+: ORR 78\%, median PFS 22.1 months
    \item HR status significantly associated with outcomes (p=0.041)
\end{itemize}
\end{tcolorbox}

\vspace{0.3cm}

% Key Finding #3: Clinical Implications
\begin{tcolorbox}[colback=orange!5!white, colframe=orange!75!black, title=Clinical Recommendations]
\begin{itemize}
    \item Strong efficacy observed regardless of HR status (Grade 1A)
    \item HR-/HER2+ patients showed numerically superior outcomes
    \item Treatment recommended for all HER2+ MBC patients
\end{itemize}
\end{tcolorbox}

\newpage
\tableofcontents  % TOC on page 2
\newpage  % Detailed content starts page 3

Patient Cohort Analysis (Detailed Sections - Page 3+)

• Cohort Characteristics: Demographics, baseline features, patient selection criteria
• Biomarker Stratification: Molecular subtypes, genomic alterations, IHC profiles
• Treatment Exposure: Therapies received, dosing, treatment duration by subgroup
• Outcome Analysis: Response rates (ORR, DCR), survival data (OS, PFS), DOR
• Statistical Methods: Kaplan-Meier survival curves, hazard ratios, log-rank tests, Cox regression
• Subgroup Comparisons: Biomarker-stratified efficacy, forest plots, statistical significance
• Safety Profile: Adverse events by subgroup, dose modifications, discontinuations
• Clinical Recommendations: Treatment implications based on biomarker profiles
• Figures: Waterfall plots, swimmer plots, survival curves, forest plots
• Tables: Demographics table, biomarker frequency, outcomes by subgroup

Treatment Recommendation Reports (Detailed Sections - Page 3+)

Page 1 Executive Summary for Treatment Recommendations should include: 1. Report Information Box: Disease state, guideline version/date, target population 2. Key Recommendations Box (green): Top 3-5 GRADE-graded recommendations by line of therapy 3. Biomarker Decision Criteria Box (blue): Key molecular markers influencing treatment selection 4. Evidence Summary Box (gray): Major trials supporting recommendations (e.g., KEYNOTE-189, FLAURA) 5. Critical Monitoring Box (orange/red): Essential safety monitoring requirements

Detailed Sections (Page 3+):

• Clinical Context: Disease state, epidemiology, current treatment landscape
• Target Population: Patient characteristics, biomarker criteria, staging
• Evidence Review: Systematic literature synthesis, guideline summary, trial data
• Treatment Options: Available therapies with mechanism of action
• Evidence Grading: GRADE assessment for each recommendation (1A, 1B, 2A, 2B, 2C)
• Recommendations by Line: First-line, second-line, subsequent therapies
• Biomarker-Guided Selection: Decision criteria based on molecular profiles
• Treatment Algorithms: TikZ flowcharts showing decision pathways
• Monitoring Protocol: Safety assessments, efficacy monitoring, dose modifications
• Special Populations: Elderly, renal/hepatic impairment, comorbidities
• References: Full bibliography with trial names and citations

Output Format

MANDATORY FIRST PAGE REQUIREMENT:

• Page 1: Full-page executive summary with 3-5 colored tcolorbox elements
• Page 2: Table of contents (optional)
• Page 3+: Detailed sections with methods, results, figures, tables

Document Specifications:

• Primary: LaTeX/PDF with 0.5in margins for compact, data-dense presentation
• Length: Typically 5-15 pages (1 page executive summary + 4-14 pages detailed content)
• Style: Publication-ready, pharmaceutical-grade, suitable for regulatory submissions
• First Page: Always a complete executive summary spanning entire page 1 (see Document Structure section)

Visual Elements:

• Colors:
• Page 1 boxes: blue=data/information, green=biomarkers/recommendations, yellow/orange=clinical implications, red=warnings
• Recommendation boxes (green=strong recommendation, yellow=conditional, blue=research needed)
• Biomarker stratification (color-coded molecular subtypes)
• Statistical significance (color-coded p-values, hazard ratios)
• Tables:
• Demographics with baseline characteristics
• Biomarker frequency by subgroup
• Outcomes table (ORR, PFS, OS, DOR by molecular subtype)
• Adverse events by cohort
• Evidence summary tables with GRADE ratings
• Figures:
• Kaplan-Meier survival curves with log-rank p-values and number at risk tables
• Waterfall plots showing best response by patient
• Forest plots for subgroup analyses with confidence intervals
• TikZ decision algorithm flowcharts
• Swimmer plots for individual patient timelines
• Statistics: Hazard ratios with 95% CI, p-values, median survival times, landmark survival rates
• Compliance: De-identification per HIPAA Safe Harbor, confidentiality notices for proprietary data

Integration

This skill integrates with:

• scientific-writing: Citation management, statistical reporting, evidence synthesis
• clinical-reports: Medical terminology, HIPAA compliance, regulatory documentation
• scientific-schematics: TikZ flowcharts for decision algorithms and treatment pathways
• treatment-plans: Individual patient applications of cohort-derived insights (bidirectional)

Key Differentiators from Treatment-Plans Skill

Clinical Decision Support (this skill):

• Audience: Pharmaceutical companies, clinical researchers, guideline committees, medical affairs
• Scope: Population-level analyses, evidence synthesis, guideline development
• Focus: Biomarker stratification, statistical comparisons, evidence grading
• Output: Multi-page analytical documents (5-15 pages typical) with extensive figures and tables
• Use Cases: Drug development, regulatory submissions, clinical practice guidelines, medical strategy
• Example: "Analyze 60 HER2+ breast cancer patients by hormone receptor status with survival outcomes"

Treatment-Plans Skill:

• Audience: Clinicians, patients, care teams
• Scope: Individual patient care planning
• Focus: SMART goals, patient-specific interventions, monitoring plans
• Output: Concise 1-4 page actionable care plans
• Use Cases: Bedside clinical care, EMR documentation, patient-centered planning
• Example: "Create treatment plan for a 55-year-old patient with newly diagnosed type 2 diabetes"

When to use each:

• Use clinical-decision-support for: cohort analyses, biomarker stratification studies, treatment guideline development, pharmaceutical strategy documents
• Use treatment-plans for: individual patient care plans, treatment protocols for specific patients, bedside clinical documentation

Example Usage

Patient Cohort Analysis

Example 1: NSCLC Biomarker Stratification

> Analyze a cohort of 45 NSCLC patients stratified by PD-L1 expression (<1%, 1-49%, ≥50%) 
> receiving pembrolizumab. Include outcomes: ORR, median PFS, median OS with hazard ratios 
> comparing PD-L1 ≥50% vs <50%. Generate Kaplan-Meier curves and waterfall plot.

Example 2: GBM Molecular Subtype Analysis

> Generate cohort analysis for 30 GBM patients classified into Cluster 1 (Mesenchymal-Immune-Active) 
> and Cluster 2 (Proneural) molecular subtypes. Compare outcomes including median OS, 6-month PFS rate, 
> and response to TMZ+bevacizumab. Include biomarker profile table and statistical comparison.

Example 3: Breast Cancer HER2 Cohort

> Analyze 60 HER2-positive metastatic breast cancer patients treated with trastuzumab-deruxtecan, 
> stratified by prior trastuzumab exposure (yes/no). Include ORR, DOR, median PFS with forest plot 
> showing subgroup analyses by hormone receptor status, brain metastases, and number of prior lines.

Treatment Recommendation Report

Example 1: HER2+ Metastatic Breast Cancer Guidelines

> Create evidence-based treatment recommendations for HER2-positive metastatic breast cancer including 
> biomarker-guided therapy selection. Use GRADE system to grade recommendations for first-line 
> (trastuzumab+pertuzumab+taxane), second-line (trastuzumab-deruxtecan), and third-line options. 
> Include decision algorithm flowchart based on brain metastases, hormone receptor status, and prior therapies.

Example 2: Advanced NSCLC Treatment Algorithm

> Generate treatment recommendation report for advanced NSCLC based on PD-L1 expression, EGFR mutation, 
> ALK rearrangement, and performance status. Include GRADE-graded recommendations for each molecular subtype, 
> TikZ flowchart for biomarker-directed therapy selection, and evidence tables from KEYNOTE-189, FLAURA, 
> and CheckMate-227 trials.

Example 3: Multiple Myeloma Line-of-Therapy Sequencing

> Create treatment algorithm for newly diagnosed multiple myeloma through relapsed/refractory setting. 
> Include GRADE recommendations for transplant-eligible vs ineligible, high-risk cytogenetics considerations, 
> and sequencing of daratumumab, carfilzomib, and CAR-T therapy. Provide flowchart showing decision points 
> at each line of therapy.

Key Features

Biomarker Classification

• Genomic: Mutations, CNV, gene fusions
• Expression: RNA-seq, IHC scores
• Molecular subtypes: Disease-specific classifications
• Clinical actionability: Therapy selection guidance

Outcome Metrics

• Survival: OS (overall survival), PFS (progression-free survival)
• Response: ORR (objective response rate), DOR (duration of response), DCR (disease control rate)
• Quality: ECOG performance status, symptom burden
• Safety: Adverse events, dose modifications

Statistical Methods

• Survival analysis: Kaplan-Meier curves, log-rank tests
• Group comparisons: t-tests, chi-square, Fisher's exact
• Effect sizes: Hazard ratios, odds ratios with 95% CI
• Significance: p-values, multiple testing corrections

Evidence Grading

GRADE System

• 1A: Strong recommendation, high-quality evidence
• 1B: Strong recommendation, moderate-quality evidence
• 2A: Weak recommendation, high-quality evidence
• 2B: Weak recommendation, moderate-quality evidence
• 2C: Weak recommendation, low-quality evidence

Recommendation Strength

• Strong: Benefits clearly outweigh risks
• Conditional: Trade-offs exist, patient values important
• Research: Insufficient evidence, clinical trials needed

Best Practices

For Cohort Analyses

1. Patient Selection Transparency: Clearly document inclusion/exclusion criteria, patient flow, and reasons for exclusions 2. Biomarker Clarity: Specify assay methods, platforms (e.g., FoundationOne, Caris), cut-points, and validation status 3. Statistical Rigor:

• Report hazard ratios with 95% confidence intervals, not just p-values
• Include median follow-up time for survival analyses
• Specify statistical tests used (log-rank, Cox regression, Fisher's exact)
• Account for multiple comparisons when appropriate

4. Outcome Definitions: Use standard criteria:

• Response: RECIST 1.1, iRECIST for immunotherapy
• Adverse events: CTCAE version 5.0
• Performance status: ECOG or Karnofsky

5. Survival Data Presentation:

• Median OS/PFS with 95% CI
• Landmark survival rates (6-month, 12-month, 24-month)
• Number at risk tables below Kaplan-Meier curves
• Censoring clearly indicated

6. Subgroup Analyses: Pre-specify subgroups; clearly label exploratory vs pre-planned analyses 7. Data Completeness: Report missing data and how it was handled

For Treatment Recommendation Reports

1. Evidence Grading Transparency:

• Use GRADE system consistently (1A, 1B, 2A, 2B, 2C)
• Document rationale for each grade
• Clearly state quality of evidence (high, moderate, low, very low)

2. Comprehensive Evidence Review:

• Include phase 3 randomized trials as primary evidence
• Supplement with phase 2 data for emerging therapies
• Note real-world evidence and meta-analyses
• Cite trial names (e.g., KEYNOTE-189, CheckMate-227)

3. Biomarker-Guided Recommendations:

• Link specific biomarkers to therapy recommendations
• Specify testing methods and validated assays
• Include FDA/EMA approval status for companion diagnostics

4. Clinical Actionability: Every recommendation should have clear implementation guidance 5. Decision Algorithm Clarity: TikZ flowcharts should be unambiguous with clear yes/no decision points 6. Special Populations: Address elderly, renal/hepatic impairment, pregnancy, drug interactions 7. Monitoring Guidance: Specify safety labs, imaging, and frequency 8. Update Frequency: Date recommendations and plan for periodic updates

General Best Practices

1. First Page Executive Summary (MANDATORY):

• ALWAYS create a complete executive summary on page 1 that spans the entire first page
• Use 3-5 colored tcolorbox elements to highlight key findings
• No table of contents or detailed sections on page 1
• Use \thispagestyle{empty} and end with \newpage
• This is the single most important page - it should be scannable in 60 seconds

2. De-identification: Remove all 18 HIPAA identifiers before document generation (Safe Harbor method) 3. Regulatory Compliance: Include confidentiality notices for proprietary pharmaceutical data 4. Publication-Ready Formatting: Use 0.5in margins, professional fonts, color-coded sections 5. Reproducibility: Document all statistical methods to enable replication 6. Conflict of Interest: Disclose pharmaceutical funding or relationships when applicable 7. Visual Hierarchy: Use colored boxes consistently (blue=data, green=biomarkers, yellow/orange=recommendations, red=warnings)

References

See the references/ directory for detailed guidance on:

• Patient cohort analysis and stratification methods
• Treatment recommendation development
• Clinical decision algorithms
• Biomarker classification and interpretation
• Outcome analysis and statistical methods
• Evidence synthesis and grading systems

Templates

See the assets/ directory for LaTeX templates:

• cohort_analysis_template.tex - Biomarker-stratified patient cohort analysis with statistical comparisons
• treatment_recommendation_template.tex - Evidence-based clinical practice guidelines with GRADE grading
• clinical_pathway_template.tex - TikZ decision algorithm flowcharts for treatment sequencing
• biomarker_report_template.tex - Molecular subtype classification and genomic profile reports

Template Features:

• 0.5in margins for compact presentation
• Color-coded recommendation boxes
• Professional tables for demographics, biomarkers, outcomes
• Built-in support for Kaplan-Meier curves, waterfall plots, forest plots
• GRADE evidence grading tables
• Confidentiality headers for pharmaceutical documents

Scripts

See the scripts/ directory for analysis and visualization tools:

• generate_survival_analysis.py - Kaplan-Meier curve generation with log-rank tests, hazard ratios, 95% CI
• create_waterfall_plot.py - Best response visualization for cohort analyses
• create_forest_plot.py - Subgroup analysis visualization with confidence intervals
• create_cohort_tables.py - Demographics, biomarker frequency, and outcomes tables
• build_decision_tree.py - TikZ flowchart generation for treatment algorithms
• biomarker_classifier.py - Patient stratification algorithms by molecular subtype
• calculate_statistics.py - Hazard ratios, Cox regression, log-rank tests, Fisher's exact
• validate_cds_document.py - Quality and compliance checks (HIPAA, statistical reporting standards)
• grade_evidence.py - Automated GRADE assessment helper for treatment recommendations

Example: GBM Molecular Subtype Cohort Analysis

Clinical Context

This example demonstrates a patient cohort analysis stratified by molecular biomarkers, similar to the GBM Mesenchymal-Immune-Active cluster analysis provided as reference.

Cohort Overview

Disease: Glioblastoma (GBM), IDH-wild-type

Study Population: n=60 patients with newly diagnosed GBM treated with standard Stupp protocol (temozolomide + radiation → adjuvant temozolomide)

Molecular Classification: Verhaak 2010 subtypes with immune signature refinement

• Group A: Mesenchymal-Immune-Active subtype (n=18, 30%)
• Group B: Other molecular subtypes (Proneural, Classical, Neural) (n=42, 70%)

Study Period: January 2019 - December 2022

Data Source: Single academic medical center, retrospective cohort analysis

Biomarker Classification

Mesenchymal-Immune-Active Subtype Characteristics

Molecular Features:

• NF1 alterations (mutations or deletions): 72% (13/18)
• High YKL-40 (CHI3L1) expression: 100% (18/18, median z-score +2.8)
• Immune gene signature: Elevated (median ESTIMATE immune score +1250)
• CD163+ macrophage infiltration: High density (median 195 cells/mm², range 120-340)
• MES (mesenchymal) signature score: >0.5 (all patients)

Clinical Characteristics:

• Median age: 64 years (range 42-76)
• Male: 61% (11/18)
• Tumor location: Temporal lobe predominant (55%)
• Multifocal disease: 33% (6/18) - higher than overall cohort

Comparison Groups (Other Subtypes)

Molecular Features:

• Proneural: n=15 (25%) - PDGFRA amplification, younger age
• Classical: n=18 (30%) - EGFR amplification, chromosome 7+/10-
• Neural: n=9 (15%) - neuronal markers, may include normal tissue

Treatment Outcomes

Response Assessment (RANO Criteria)

Objective Response Rate (after chemoradiation, ~3 months):

• Mesenchymal-Immune-Active: 6/18 (33%) - CR 0, PR 6
• Other subtypes: 18/42 (43%) - CR 1, PR 17
• p = 0.48 (Fisher's exact)

Interpretation: No significant difference in initial response rates

Survival Outcomes

Progression-Free Survival (PFS):

• Mesenchymal-Immune-Active: Median 7.2 months (95% CI 5.8-9.1)
• Other subtypes: Median 9.5 months (95% CI 8.1-11.3)
• Hazard Ratio: 1.58 (95% CI 0.89-2.81), p = 0.12
• 6-month PFS rate: 61% vs 74%

Overall Survival (OS):

• Mesenchymal-Immune-Active: Median 12.8 months (95% CI 10.2-15.4)
• Other subtypes: Median 16.3 months (95% CI 14.7-18.9)
• Hazard Ratio: 1.72 (95% CI 0.95-3.11), p = 0.073
• 12-month OS rate: 55% vs 68%
• 24-month OS rate: 17% vs 31%

Interpretation: Trend toward worse survival in mesenchymal-immune-active subtype, not reaching statistical significance in this cohort size

Response to Bevacizumab at Recurrence

Subset Analysis (patients receiving bevacizumab at first recurrence, n=35):

• Mesenchymal-Immune-Active: n=12
• ORR: 58% (7/12)
• Median PFS2 (from bevacizumab start): 6.8 months
• Other subtypes: n=23
• ORR: 35% (8/23)
• Median PFS2: 4.2 months
• p = 0.19 (Fisher's exact for ORR)
• HR for PFS2: 0.62 (95% CI 0.29-1.32), p = 0.21

Interpretation: Exploratory finding suggesting enhanced benefit from bevacizumab in mesenchymal-immune-active subtype (not statistically significant with small sample)

Safety Profile

Treatment-Related Adverse Events (Temozolomide):

No significant differences in toxicity between molecular subtypes:

• Lymphopenia (any grade): 89% vs 86%, p = 0.77
• Thrombocytopenia (grade 3-4): 22% vs 19%, p = 0.79
• Fatigue (any grade): 94% vs 90%, p = 0.60
• Treatment discontinuation: 17% vs 14%, p = 0.77

Clinical Implications

Treatment Recommendations

For Mesenchymal-Immune-Active GBM:

1. First-Line: Standard Stupp protocol (no change based on subtype)

• Evidence: No proven benefit for alternative first-line strategies
• GRADE: 1A (strong recommendation, high-quality evidence)

2. At Recurrence - Consider Bevacizumab Earlier:

• Rationale: Exploratory data suggesting enhanced anti-angiogenic response
• Evidence: Mesenchymal GBM has high VEGF expression, angiogenic phenotype
• GRADE: 2C (conditional recommendation, low-quality evidence from subset)

3. Clinical Trial Enrollment - Immunotherapy Combinations:

• Rationale: High immune cell infiltration may predict immunotherapy benefit
• Targets: PD-1/PD-L1 blockade ± anti-CTLA-4 or anti-angiogenic agents
• Evidence: Ongoing trials (CheckMate-498, CheckMate-548 showed negative results, but did not select for immune-active)
• GRADE: R (research recommendation)

For Other GBM Subtypes:

• Standard treatment per NCCN guidelines
• Consider tumor treating fields (Optune) after radiation completion
• Clinical trials based on specific molecular features (EGFR amplification → EGFR inhibitor trials)

Prognostic Information

Counseling Patients:

• Mesenchymal-immune-active subtype associated with trend toward shorter survival (12.8 vs 16.3 months)
• Not definitive due to small sample size and confidence intervals overlapping
• Prospective validation needed
• Should not alter standard first-line treatment

Study Limitations

1. Small Sample Size: n=18 in mesenchymal-immune-active group limits statistical power 2. Retrospective Design: Potential selection bias, unmeasured confounders 3. Single Institution: May not generalize to other populations 4. Heterogeneous Recurrence Treatment: Not all patients received bevacizumab; treatment selection bias 5. Molecular Classification: Based on bulk tumor RNA-seq; intratumoral heterogeneity not captured 6. No Central Pathology Review: Molecular classification performed locally

Future Directions

1. Prospective Validation: Confirm survival differences in independent cohort (n>100 per group for adequate power) 2. Biomarker Testing: Develop clinically feasible assay for mesenchymal-immune subtype identification 3. Clinical Trial Design: Immunotherapy combinations targeting mesenchymal-immune-active GBM specifically 4. Mechanistic Studies: Investigate why mesenchymal-immune GBM may respond better to bevacizumab 5. Longitudinal Analysis: Track molecular subtype evolution over treatment course

Data Presentation Example

Baseline Characteristics Table

Characteristic                    Mesenchymal-IA (n=18)  Other (n=42)  p-value
Age, years (median [IQR])         64 [56-71]            61 [53-68]    0.42
Sex, n (%)
  Male                            11 (61%)              24 (57%)      0.78
  Female                          7 (39%)               18 (43%)
ECOG PS, n (%)
  0-1                             15 (83%)              37 (88%)      0.63
  2                               3 (17%)               5 (12%)
Tumor location
  Frontal                         4 (22%)               15 (36%)      0.35
  Temporal                        10 (56%)              16 (38%)
  Parietal/Occipital              4 (22%)               11 (26%)
Extent of resection
  Gross total                     8 (44%)               22 (52%)      0.58
  Subtotal                        10 (56%)              20 (48%)
MGMT promoter methylated          5 (28%)               18 (43%)      0.27

Survival Outcomes Summary

Endpoint                          Mesenchymal-IA        Other         HR (95% CI)        p-value
Median PFS, months (95% CI)       7.2 (5.8-9.1)        9.5 (8.1-11.3) 1.58 (0.89-2.81)   0.12
6-month PFS rate                  61%                  74%
Median OS, months (95% CI)        12.8 (10.2-15.4)     16.3 (14.7-18.9) 1.72 (0.95-3.11) 0.073
12-month OS rate                  55%                  68%
24-month OS rate                  17%                  31%

Key Takeaways

1. Molecular heterogeneity exists in GBM with distinct subtypes 2. Mesenchymal-immune-active subtype characterized by NF1 alterations, immune infiltration 3. Trend toward worse prognosis but not statistically significant (power limitations) 4. Potential bevacizumab benefit hypothesis-generating, requires prospective validation 5. Immunotherapy target: High immune infiltration rational for checkpoint inhibitor trials 6. Clinical implementation pending: Need prospective validation before routine subtyping

References

1. Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. 2. Wang Q, et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017;32(1):42-56. 3. Stupp R, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. NEJM. 2005;352(10):987-996. 4. Gilbert MR, et al. Bevacizumab for Newly Diagnosed Glioblastoma. NEJM. 2014;370(8):699-708. 5. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2024.

---

This example demonstrates:

• Biomarker-based stratification methodology
• Outcome reporting with appropriate statistics
• Clinical contextualization of findings
• Evidence-based recommendations with grading
• Transparent limitation discussion
• Structure suitable for pharmaceutical/clinical research documentation

Recommendation Strength Guide

GRADE Framework for Clinical Recommendations

Components of a Recommendation

Every clinical recommendation should address:

1. Population: Who should receive the intervention? 2. Intervention: What specific treatment/action? 3. Comparator: Compared to what alternative? 4. Outcome: What are the expected results? 5. Strength: How strong is the recommendation? 6. Quality of Evidence: How confident are we in the evidence?

Recommendation Strength (Grade 1 vs Grade 2)

Strong Recommendation (Grade 1)

When to Use:

• Desirable effects clearly outweigh undesirable effects (or vice versa)
• High or moderate quality evidence
• Values and preferences: Little variability expected
• Resource implications: Cost-effective or cost considerations minor

Wording: "We recommend..." or "Clinicians should..."

Implications:

• Most patients should receive the recommended intervention
• Adherence to recommendation could be a quality indicator
• Policy-makers can adapt as performance measure

Examples:

STRONG RECOMMENDATION FOR (Grade 1):

"We recommend osimertinib 80 mg daily as first-line therapy for adults with 
advanced NSCLC harboring EGFR exon 19 deletion or L858R mutation (Strong 
recommendation, High-quality evidence - GRADE 1A)."

Rationale:
- Large PFS benefit: 18.9 vs 10.2 months (HR 0.46, p<0.001)
- OS benefit: 38.6 vs 31.8 months (HR 0.80, p=0.046)  
- Better tolerability: Lower grade 3-4 AEs
- Evidence: High-quality (large RCT, low risk of bias)
- Benefits clearly outweigh harms

STRONG RECOMMENDATION AGAINST (Grade 1):

"We recommend against using bevacizumab in the first-line treatment of newly 
diagnosed glioblastoma to improve overall survival (Strong recommendation against, 
High-quality evidence - GRADE 1A)."

Rationale:
- No OS benefit: HR 0.88 (0.76-1.02), p=0.10 (AVAglio trial)
- Toxicity: Increased grade ≥3 AEs (66% vs 52%)
- Evidence: High-quality (two large phase 3 RCTs)
- Harms outweigh lack of survival benefit

Conditional/Weak Recommendation (Grade 2)

When to Use:

• Desirable and undesirable effects closely balanced
• Low or very low quality evidence
• Values and preferences: Substantial variability
• Resource implications: High cost or limited access

Wording: "We suggest..." or "Clinicians might..."

Implications:

• Different choices will be appropriate for different patients
• Shared decision-making essential
• Policy-making requires substantial debate and stakeholder involvement

Examples:

CONDITIONAL RECOMMENDATION FOR (Grade 2):

"We suggest considering maintenance pemetrexed after first-line platinum-pemetrexed 
chemotherapy for advanced non-squamous NSCLC in patients without disease progression 
(Conditional recommendation, Moderate-quality evidence - GRADE 2B)."

Rationale:
- Modest PFS benefit: 4.0 vs 2.0 months (HR 0.62)
- No OS benefit: 13.9 vs 11.0 months (HR 0.79, p=0.23)
- Toxicity: Continued chemotherapy burden
- Quality of life: Trade-off between symptom control and treatment side effects
- Patient values: Some prioritize time off treatment, others prioritize disease control
- Shared decision-making essential

CONDITIONAL RECOMMENDATION - EITHER OPTION ACCEPTABLE (Grade 2):

"We suggest either pembrolizumab monotherapy OR pembrolizumab plus platinum-doublet 
chemotherapy as first-line treatment for PD-L1 ≥50% NSCLC, based on patient 
preferences and clinical factors (Conditional recommendation, High-quality evidence - 
GRADE 2A)."

Rationale:
- Both regimens NCCN Category 1 preferred
- Monotherapy: Less toxicity, oral vs IV, better quality of life
- Combination: Higher ORR (48% vs 39%), numerically longer PFS
- OS: Similar between strategies
- Patient values: Varies widely (tolerability vs response rate priority)

Evidence Quality (⊕⊕⊕⊕ to ⊕○○○)

High Quality (⊕⊕⊕⊕)

• Further research very unlikely to change confidence in effect estimate
• Consistent results from well-designed RCTs
• No serious limitations
• Direct evidence (target population, intervention, outcomes)
• Precise estimate (narrow CI)

Example: FLAURA trial for osimertinib in EGFR+ NSCLC - Large RCT, consistent results, low risk of bias, direct outcomes

Moderate Quality (⊕⊕⊕○)

• Further research likely to impact confidence and may change estimate
• RCTs with some limitations OR very strong evidence from observational studies
• Some inconsistency, indirectness, imprecision, or publication bias

Example: Single RCT with some limitations, or multiple RCTs with moderate heterogeneity

Low Quality (⊕⊕○○)

• Further research very likely to have important impact on confidence in estimate
• Observational studies OR RCTs with serious limitations
• Serious issues with consistency, directness, precision, or bias

Example: Well-conducted cohort study, or RCT with high attrition and unclear allocation concealment

Very Low Quality (⊕○○○)

• Estimate of effect very uncertain
• Case series, expert opinion, mechanistic reasoning
• Very serious limitations

Example: Retrospective case series, expert consensus without systematic review

Combining Strength and Quality

All Nine Possible Combinations

*Rare: Strong recommendations usually require at least moderate-quality evidence

Unusual Combinations (When They Occur)

Strong Recommendation with Low Quality Evidence (Grade 1C)

Rare, but can occur when:

• Large magnitude of effect from observational data (RR >5 or <0.2)
• Low quality evidence, but clear benefit-harm balance
• Example: Anticoagulation for atrial fibrillation (before RCTs, strong observational data)

Weak Recommendation with High Quality Evidence (Grade 2A)

Occurs when:

• Benefits and harms closely balanced
• Patient values highly variable
• Example: Aspirin for primary prevention in low-risk individuals (benefits small, bleeding risk present, patient values vary)

Wording Templates

Strong Recommendations

FOR (↑↑):

• "We recommend [intervention] for [population]."
• "Clinicians should [action]."
• "[Intervention] is recommended."

AGAINST (↓↓):

• "We recommend against [intervention] for [population]."
• "Clinicians should not [action]."
• "[Intervention] is not recommended."

Conditional/Weak Recommendations

FOR (↑):

• "We suggest [intervention] for [population]."
• "Clinicians might consider [action]."
• "[Intervention] may be considered for selected patients."

AGAINST (↓):

• "We suggest not using [intervention] for [population]."
• "Clinicians might avoid [action]."
• "[Intervention] is generally not recommended."

EITHER ACCEPTABLE:

• "We suggest either [option A] or [option B] based on patient preferences."
• "Either approach is reasonable."

Color Coding for Visual Documents

Strong Recommendations (Green Background):

• RGB(0, 153, 76) or #009954
• Clear visual priority
• Use for Grade 1A, 1B

Conditional Recommendations (Yellow Background):

• RGB(255, 193, 7) or #FFC107
• Indicates discussion needed
• Use for Grade 2A, 2B, 2C

Research/Investigational (Blue Background):

• RGB(33, 150, 243) or #2196F3
• Clinical trial consideration
• Insufficient evidence for standard care

Not Recommended (Red Border/Background):

• RGB(220, 20, 60) or #DC143C
• Strong recommendation against
• Evidence of harm or no benefit

Common Scenarios

Scenario 1: Strong Evidence, Clear Benefit-Harm Balance

Example: Pembrolizumab for PD-L1 ≥50% NSCLC

• Evidence: Large phase 3 RCT (KEYNOTE-024), n=305, well-designed
• Results: PFS HR 0.50 (0.37-0.68), OS HR 0.60 (0.41-0.89)
• Toxicity: Lower grade 3-5 AEs than chemotherapy (27% vs 53%)
• Patient values: Most prioritize efficacy and tolerability

Recommendation: STRONG FOR (Grade 1A)

Scenario 2: Moderate Evidence, Balanced Trade-Offs

Example: Adjuvant immunotherapy for resected melanoma

• Evidence: RCT showing relapse-free survival benefit, OS data immature
• Results: Recurrence risk reduced but ongoing toxicity
• Toxicity: Immune-related AEs requiring steroids (some severe)
• Cost: High annual cost for 12 months treatment
• Patient values: Variable (some prioritize recurrence prevention, others avoid toxicity)

Recommendation: CONDITIONAL FOR (Grade 2B)

Scenario 3: Low Evidence, but Severe Consequence

Example: Anticoagulation for prosthetic heart valve

• Evidence: No RCTs (would be unethical), observational data and mechanistic reasoning
• Consequence: Very high thromboembolic risk without anticoagulation
• Benefit-harm: Clear despite low quality evidence

Recommendation: STRONG FOR (Grade 1C)

Scenario 4: High Evidence, but Patient Preferences Vary

Example: Breast reconstruction after mastectomy

• Evidence: High-quality data on outcomes and satisfaction
• Trade-offs: Cosmetic benefit vs additional surgery, recovery time
• Values: Highly personal decision, wide preference variability

Recommendation: CONDITIONAL (Grade 2A) - discuss options, patient decides

Documentation Template

RECOMMENDATION: [State recommendation clearly]

Strength: [STRONG / CONDITIONAL]
Quality of Evidence: [HIGH / MODERATE / LOW / VERY LOW]
GRADE: [1A / 1B / 2A / 2B / 2C]

Evidence Summary:
- Primary study: [Citation]
- Design: [RCT / Observational / Meta-analysis]
- Sample size: n = [X]
- Results: [Primary outcome with effect size, CI, p-value]
- Quality assessment: [Strengths and limitations]

Benefits:
- [Quantified benefit 1]
- [Quantified benefit 2]

Harms:
- [Quantified harm 1]
- [Quantified harm 2]

Balance: [Benefits clearly outweigh harms / Close balance requiring discussion / etc.]

Values and Preferences: [Little variability / Substantial variability]

Cost Considerations: [If relevant]

Guideline Concordance:
- NCCN: [Category and recommendation]
- ASCO: [Recommendation]
- ESMO: [Grade and recommendation]

Quality Checklist

Before finalizing recommendations, verify:

• [ ] Recommendation statement is clear and actionable
• [ ] Strength is explicitly stated (strong vs conditional)
• [ ] Quality of evidence is graded (high/moderate/low/very low)
• [ ] GRADE notation provided (1A, 1B, 2A, 2B, 2C)
• [ ] Evidence is cited with specific study results
• [ ] Benefits are quantified (effect sizes with CIs)
• [ ] Harms are quantified (AE rates)
• [ ] Balance of benefits/harms is explained
• [ ] Patient values consideration is addressed (if conditional)
• [ ] Alternative options are mentioned
• [ ] Guideline concordance is documented
• [ ] Special populations are addressed (elderly, renal/hepatic impairment)
• [ ] Monitoring requirements are specified

Clinical Decision Algorithms Guide

Overview

Clinical decision algorithms provide systematic, step-by-step guidance for diagnosis, treatment selection, and patient management. This guide covers algorithm development, validation, and visual presentation using decision trees and flowcharts.

Algorithm Design Principles

Key Components

Decision Nodes

• Question/Criteria: Clear, measurable clinical parameter
• Binary vs Multi-Way: Yes/no (simple) vs multiple options (complex)
• Objective: Lab value, imaging finding vs Subjective: Clinical judgment

Action Nodes

• Treatment: Specific intervention with dosing
• Test: Additional diagnostic procedure
• Referral: Specialist consultation, higher level of care
• Observation: Watchful waiting with defined follow-up

Terminal Nodes

• Outcome: Final decision point
• Follow-up: Schedule for reassessment
• Exit criteria: When to exit algorithm

Design Criteria

Clarity

• Unambiguous decision points
• Mutually exclusive pathways
• No circular loops (unless intentional reassessment cycles)
• Clear entry and exit points

Clinical Validity

• Evidence-based decision criteria
• Validated cut-points for biomarkers
• Guideline-concordant recommendations
• Expert consensus where evidence limited

Usability

• Maximum 7 decision points per pathway (cognitive load)
• Visual hierarchy (most common path highlighted)
• Printable single-page format preferred
• Color coding for urgency/safety

Completeness

• All possible scenarios covered
• Default pathway for edge cases
• Safety-net provisions for unusual presentations
• Escalation criteria clearly stated

Clinical Decision Trees

Diagnostic Algorithms

Chest Pain Evaluation Algorithm

Entry: Patient with chest pain

├─ STEMI Criteria? (ST elevation ≥1mm in ≥2 contiguous leads)
│  ├─ YES → Activate cath lab, aspirin 325mg, heparin, clopidogrel 600mg
│  │        Transfer for primary PCI (goal door-to-balloon <90 minutes)
│  └─ NO → Continue evaluation

├─ High-Risk Features? (Hemodynamic instability, arrhythmia, troponin elevation)
│  ├─ YES → Admit CCU, serial troponins, cardiology consultation
│  │        Consider early angiography if NSTEMI
│  └─ NO → Calculate TIMI or HEART score

├─ TIMI Score 0-1 or HEART Score 0-3? (Low risk)
│  ├─ YES → Observe 6-12 hours, serial troponins, stress test if negative
│  │        Discharge if all negative with cardiology follow-up in 72 hours
│  └─ NO → TIMI 2-4 or HEART 4-6 (Intermediate risk)

├─ TIMI Score 2-4 or HEART Score 4-6? (Intermediate risk)
│  ├─ YES → Admit telemetry, serial troponins, stress imaging vs CT angiography
│  │        Medical management: Aspirin, statin, beta-blocker
│  └─ NO → TIMI ≥5 or HEART ≥7 (High risk) → Treat as NSTEMI

Decision Endpoint: Risk-stratified pathway with 30-day event rate documented

Pulmonary Embolism Diagnostic Algorithm (Wells Criteria)

Entry: Suspected PE

Step 1: Calculate Wells Score
  Clinical features points:
  - Clinical signs of DVT: 3 points
  - PE more likely than alternative diagnosis: 3 points  
  - Heart rate >100: 1.5 points
  - Immobilization/surgery in past 4 weeks: 1.5 points
  - Previous PE/DVT: 1.5 points
  - Hemoptysis: 1 point
  - Malignancy: 1 point

Step 2: Risk Stratify
  ├─ Wells Score ≤4 (PE unlikely)
  │  └─ D-dimer test
  │     ├─ D-dimer negative (<500 ng/mL) → PE excluded, consider alternative diagnosis
  │     └─ D-dimer positive (≥500 ng/mL) → CTPA
  │
  └─ Wells Score >4 (PE likely)
     └─ CTPA (skip D-dimer)

Step 3: CTPA Results
  ├─ Positive for PE → Risk stratify severity
  │  ├─ Massive PE (hypotension, shock) → Thrombolytics vs embolectomy
  │  ├─ Submassive PE (RV strain, troponin+) → Admit ICU, consider thrombolytics
  │  └─ Low-risk PE → Anticoagulation, consider outpatient management
  │
  └─ Negative for PE → PE excluded, investigate alternative diagnosis

Step 4: Treatment Decision (if PE confirmed)
  ├─ Absolute contraindication to anticoagulation?
  │  ├─ YES → IVC filter placement, treat underlying condition
  │  └─ NO → Anticoagulation therapy
  │
  ├─ Cancer-associated thrombosis?
  │  ├─ YES → LMWH preferred (edoxaban alternative)
  │  └─ NO → DOAC preferred (apixaban, rivaroxaban, edoxaban)
  │
  └─ Duration: Minimum 3 months, extended if unprovoked or recurrent

Treatment Selection Algorithms

NSCLC First-Line Treatment Algorithm

Entry: Advanced/Metastatic NSCLC, adequate PS (ECOG 0-2)

Step 1: Biomarker Testing Complete?
  ├─ NO → Reflex testing: EGFR, ALK, ROS1, BRAF, PD-L1, consider NGS
  │       Hold systemic therapy pending results (unless rapidly progressive)
  └─ YES → Proceed to Step 2

Step 2: Actionable Genomic Alteration?
  ├─ EGFR exon 19 deletion or L858R → Osimertinib 80mg daily
  │  └─ Alternative: Erlotinib, gefitinib, afatinib (less preferred)
  │
  ├─ ALK rearrangement → Alectinib 600mg BID
  │  └─ Alternatives: Brigatinib, lorlatinib, crizotinib (less preferred)
  │
  ├─ ROS1 rearrangement → Crizotinib 250mg BID or entrectinib
  │
  ├─ BRAF V600E → Dabrafenib + trametinib
  │
  ├─ MET exon 14 skipping → Capmatinib or tepotinib
  │
  ├─ RET rearrangement → Selpercatinib or pralsetinib
  │
  ├─ NTRK fusion → Larotrectinib or entrectinib
  │
  ├─ KRAS G12C → Sotorasib or adagrasib (if no other options)
  │
  └─ NO actionable alteration → Proceed to Step 3

Step 3: PD-L1 Testing Result?
  ├─ PD-L1 ≥50% (TPS)
  │  ├─ Option 1: Pembrolizumab 200mg Q3W (monotherapy, NCCN Category 1)
  │  ├─ Option 2: Pembrolizumab + platinum doublet chemotherapy
  │  └─ Option 3: Atezolizumab + bevacizumab + carboplatin + paclitaxel
  │
  ├─ PD-L1 1-49% (TPS)
  │  ├─ Preferred: Pembrolizumab + platinum doublet chemotherapy
  │  └─ Alternative: Platinum doublet chemotherapy alone
  │
  └─ PD-L1 <1% (TPS)
     ├─ Preferred: Pembrolizumab + platinum doublet chemotherapy
     └─ Alternative: Platinum doublet chemotherapy ± bevacizumab

Step 4: Platinum Doublet Selection (if applicable)
  ├─ Squamous histology
  │  └─ Carboplatin AUC 6 + paclitaxel 200 mg/m² Q3W (4 cycles)
  │      or Carboplatin AUC 5 + nab-paclitaxel 100 mg/m² D1,8,15 Q4W
  │
  └─ Non-squamous histology  
     └─ Carboplatin AUC 6 + pemetrexed 500 mg/m² Q3W (4 cycles)
         Continue pemetrexed maintenance if responding
         Add bevacizumab 15 mg/kg if eligible (no hemoptysis, brain mets)

Step 5: Monitoring and Response Assessment
  - Imaging every 6 weeks for first 12 weeks, then every 9 weeks
  - Continue until progression or unacceptable toxicity
  - At progression, proceed to second-line algorithm

Heart Failure Management Algorithm (AHA/ACC Guidelines)

Entry: Heart Failure Diagnosis Confirmed

Step 1: Determine HF Type
  ├─ HFrEF (EF ≤40%)
  │  └─ Proceed to Guideline-Directed Medical Therapy (GDMT)
  │
  ├─ HFpEF (EF ≥50%)
  │  └─ Treat comorbidities, diuretics for congestion, consider SGLT2i
  │
  └─ HFmrEF (EF 41-49%)
     └─ Consider HFrEF GDMT, evidence less robust

Step 2: GDMT for HFrEF (All patients unless contraindicated)

Quadruple Therapy (Class 1 recommendations):

1. ACE Inhibitor/ARB/ARNI
   ├─ Preferred: Sacubitril-valsartan 49/51mg BID → titrate to 97/103mg BID
   │  └─ If ACE-I naïve or taking <10mg enalapril equivalent
   ├─ Alternative: ACE-I (enalapril, lisinopril, ramipril) to target dose
   └─ Alternative: ARB (losartan, valsartan) if ACE-I intolerant

2. Beta-Blocker (start low, titrate slowly)
   ├─ Bisoprolol 1.25mg daily → 10mg daily target
   ├─ Metoprolol succinate 12.5mg daily → 200mg daily target
   └─ Carvedilol 3.125mg BID → 25mg BID target (50mg BID if >85kg)

3. Mineralocorticoid Receptor Antagonist (MRA)
   ├─ Spironolactone 12.5-25mg daily → 50mg daily target
   └─ Eplerenone 25mg daily → 50mg daily target
   └─ Contraindications: K >5.0, CrCl <30 mL/min

4. SGLT2 Inhibitor (regardless of diabetes status)
   ├─ Dapagliflozin 10mg daily
   └─ Empagliflozin 10mg daily

Step 3: Additional Therapies Based on Phenotype

├─ Sinus rhythm + HR ≥70 despite beta-blocker?
│  └─ YES: Add ivabradine 5mg BID → 7.5mg BID target
│
├─ African American + NYHA III-IV?
│  └─ YES: Add hydralazine 37.5mg TID + isosorbide dinitrate 20mg TID
│           (Target: hydralazine 75mg TID + ISDN 40mg TID)
│
├─ Atrial fibrillation?
│  ├─ Rate control (target <80 bpm at rest, <110 bpm with activity)
│  └─ Anticoagulation (DOAC preferred, warfarin if valvular)
│
└─ Iron deficiency (ferritin <100 or <300 with TSAT <20%)?
   └─ YES: IV iron supplementation (ferric carboxymaltose)

Step 4: Device Therapy Evaluation

├─ EF ≤35%, NYHA II-III, LBBB with QRS ≥150 ms, sinus rhythm?
│  └─ YES: Cardiac resynchronization therapy (CRT-D)
│
├─ EF ≤35%, NYHA II-III, on GDMT ≥3 months?
│  └─ YES: ICD for primary prevention
│           (if life expectancy >1 year with good functional status)
│
└─ EF ≤35%, NYHA IV despite GDMT, or advanced HF?
   └─ Refer to advanced HF specialist
      ├─ LVAD evaluation
      ├─ Heart transplant evaluation
      └─ Palliative care consultation

Step 5: Monitoring and Titration

Weekly to biweekly visits during titration:
- Blood pressure (target SBP ≥90 mmHg)
- Heart rate (target 50-60 bpm)
- Potassium (target 4.0-5.0 mEq/L, hold MRA if >5.5)
- Creatinine (expect 10-20% increase, acceptable if <30% and stable)
- Symptoms and congestion status (daily weights, NYHA class)

Stable on GDMT:
- Visits every 3-6 months
- Echocardiogram at 3-6 months after GDMT optimization, then annually
- NT-proBNP or BNP trending (biomarker-guided therapy investigational)

Risk Stratification Tools

Cardiovascular Risk Scores

TIMI Risk Score (NSTEMI/Unstable Angina)

Score Calculation (0-7 points):
☐ Age ≥65 years (1 point)
☐ ≥3 cardiac risk factors (HTN, hyperlipidemia, diabetes, smoking, family history) (1)
☐ Known CAD (stenosis ≥50%) (1)
☐ ASA use in past 7 days (1)
☐ Severe angina (≥2 episodes in 24 hours) (1)
☐ ST deviation ≥0.5 mm (1)
☐ Elevated cardiac biomarkers (1)

Risk Stratification:
├─ Score 0-1: 5% risk of death/MI/urgent revasc at 14 days (Low)
│  └─ Management: Observation, stress test, outpatient follow-up
│
├─ Score 2: 8% risk (Low-intermediate)
│  └─ Management: Admission, medical therapy, stress imaging
│
├─ Score 3-4: 13-20% risk (Intermediate-high)
│  └─ Management: Admission, aggressive medical therapy, early invasive strategy
│
└─ Score 5-7: 26-41% risk (High)
   └─ Management: Aggressive treatment, urgent angiography (<24 hours)

CHA2DS2-VASc Score (Stroke Risk in Atrial Fibrillation)

Score Calculation:
☐ Congestive heart failure (1 point)
☐ Hypertension (1)
☐ Age ≥75 years (2)
☐ Diabetes mellitus (1)
☐ Prior stroke/TIA/thromboembolism (2)
☐ Vascular disease (MI, PAD, aortic plaque) (1)
☐ Age 65-74 years (1)
☐ Sex category (female) (1)

Maximum score: 9 points

Treatment Algorithm:
├─ Score 0 (male) or 1 (female): 0-1.3% annual stroke risk
│  └─ No anticoagulation or aspirin (Class IIb)
│
├─ Score 1 (male): 1.3% annual stroke risk
│  └─ Consider anticoagulation (Class IIa)
│      Factors: Patient preference, bleeding risk, comorbidities
│
└─ Score ≥2 (male) or ≥3 (female): ≥2.2% annual stroke risk
   └─ Anticoagulation recommended (Class I)
      ├─ Preferred: DOAC (apixaban, rivaroxaban, edoxaban, dabigatran)
      └─ Alternative: Warfarin (INR 2-3) if DOAC contraindicated

Bleeding Risk Assessment (HAS-BLED):
H - Hypertension (SBP >160)
A - Abnormal renal/liver function (1 point each)
S - Stroke history
B - Bleeding history or predisposition
L - Labile INR (if on warfarin)
E - Elderly (age >65)
D - Drugs (antiplatelet, NSAIDs) or alcohol (1 point each)

HAS-BLED ≥3: High bleeding risk → Modifiable factors, consider DOAC over warfarin

Oncology Risk Calculators

MELD Score (Hepatocellular Carcinoma Eligibility)

MELD = 3.78×ln(bilirubin mg/dL) + 11.2×ln(INR) + 9.57×ln(creatinine mg/dL) + 6.43

Interpretation:
├─ MELD <10: 1.9% 3-month mortality (Low)
│  └─ Consider resection or ablation for HCC
│
├─ MELD 10-19: 6-20% 3-month mortality (Moderate)
│  └─ Transplant evaluation if within Milan criteria
│      Milan: Single ≤5cm or ≤3 lesions each ≤3cm, no vascular invasion
│
├─ MELD 20-29: 20-45% 3-month mortality (High)
│  └─ Urgent transplant evaluation, bridge therapy (TACE, ablation)
│
└─ MELD ≥30: 50-70% 3-month mortality (Very high)
   └─ Transplant vs palliative care discussion
      Too ill for transplant if MELD >35-40 typically

Adjuvant! Online (Breast Cancer Recurrence Risk)

Input Variables:
- Age at diagnosis
- Tumor size
- Tumor grade (1-3)
- ER status
- Node status (0, 1-3, 4-9, ≥10)
- HER2 status
- Comorbidity index

Output: 10-year risk of:
- Recurrence
- Breast cancer mortality
- Overall mortality

Treatment Benefit Estimates:
- Chemotherapy: Absolute reduction in recurrence
- Endocrine therapy: Absolute reduction in recurrence
- Trastuzumab: Absolute reduction (if HER2+)

Clinical Application:
├─ Low risk (<10% recurrence): Consider endocrine therapy alone if ER+
├─ Intermediate risk (10-20%): Chemotherapy discussion, genomic assay
│  └─ Oncotype DX score <26: Endocrine therapy alone
│  └─ Oncotype DX score ≥26: Chemotherapy + endocrine therapy
└─ High risk (>20%): Chemotherapy + endocrine therapy if ER+

TikZ Flowchart Best Practices

Visual Design Principles

Node Styling

% Decision nodes (diamond)
\tikzstyle{decision} = [diamond, draw, fill=yellow!20, text width=4.5em, text centered, inner sep=0pt]

% Process nodes (rectangle)
\tikzstyle{process} = [rectangle, draw, fill=blue!20, text width=5em, text centered, rounded corners, minimum height=3em]

% Terminal nodes (rounded rectangle)
\tikzstyle{terminal} = [rectangle, draw, fill=green!20, text width=5em, text centered, rounded corners=1em, minimum height=3em]

% Input/Output (parallelogram)
\tikzstyle{io} = [trapezium, draw, fill=purple!20, text width=5em, text centered, minimum height=3em]

Color Coding by Urgency

• Red: Life-threatening, immediate action required
• Orange: Urgent, action within hours
• Yellow: Semi-urgent, action within 24-48 hours
• Green: Routine, stable clinical situation
• Blue: Informational, monitoring only

Pathway Emphasis

• Bold arrows for most common pathway
• Dashed arrows for rare scenarios
• Arrow thickness proportional to pathway frequency
• Highlight boxes around critical decision points

LaTeX TikZ Template

\documentclass{article}
\usepackage{tikz}
\usetikzlibrary{shapes, arrows, positioning}

\begin{document}

\tikzstyle{decision} = [diamond, draw, fill=yellow!20, text width=4em, text centered, inner sep=2pt, font=\small]
\tikzstyle{process} = [rectangle, draw, fill=blue!20, text width=6em, text centered, rounded corners, minimum height=2.5em, font=\small]
\tikzstyle{terminal} = [rectangle, draw, fill=green!20, text width=6em, text centered, rounded corners=8pt, minimum height=2.5em, font=\small]
\tikzstyle{alert} = [rectangle, draw=red, line width=1.5pt, fill=red!10, text width=6em, text centered, rounded corners, minimum height=2.5em, font=\small\bfseries]
\tikzstyle{arrow} = [thick,->,>=stealth]

\begin{tikzpicture}[node distance=2cm, auto]
    % Nodes
    \node [terminal] (start) {Patient presents with symptom X};
    \node [decision, below of=start] (decision1) {Criterion A met?};
    \node [alert, below of=decision1, node distance=2.5cm] (alert1) {Immediate action};
    \node [process, right of=decision1, node distance=4cm] (process1) {Standard evaluation};
    \node [terminal, below of=process1, node distance=2.5cm] (end) {Outcome};
    
    % Arrows
    \draw [arrow] (start) -- (decision1);
    \draw [arrow] (decision1) -- node {Yes} (alert1);
    \draw [arrow] (decision1) -- node {No} (process1);
    \draw [arrow] (process1) -- (end);
    \draw [arrow] (alert1) -| (end);
\end{tikzpicture}

\end{document}

Algorithm Validation

Development Process

Step 1: Literature Review and Evidence Synthesis

• Systematic review of guidelines (NCCN, ASCO, ESMO, AHA/ACC)
• Meta-analyses of clinical trials
• Expert consensus statements
• Local practice patterns and resource availability

Step 2: Draft Algorithm Development

• Multidisciplinary team input (physicians, nurses, pharmacists)
• Define decision nodes and criteria
• Specify actions and outcomes
• Identify areas of uncertainty

Step 3: Pilot Testing

• Retrospective application to historical cases (n=20-50)
• Identify scenarios not covered by algorithm
• Refine decision criteria
• Usability testing with end-users

Step 4: Prospective Validation

• Implement in clinical practice with data collection
• Track adherence rate (target >80%)
• Monitor outcomes vs historical controls
• User satisfaction surveys

Step 5: Continuous Quality Improvement

• Quarterly review of algorithm performance
• Update based on new evidence
• Address deviations and reasons for non-adherence
• Version control and change documentation

Performance Metrics

Process Metrics

• Algorithm adherence rate (% cases following algorithm)
• Time to decision (median time from presentation to treatment start)
• Completion rate (% cases reaching terminal node)

Outcome Metrics

• Appropriateness of care (concordance with guidelines)
• Clinical outcomes (mortality, morbidity, readmissions)
• Resource utilization (length of stay, unnecessary tests)
• Safety (adverse events, errors)

User Experience Metrics

• Ease of use (Likert scale survey)
• Time to use (median time to navigate algorithm)
• Perceived utility (% users reporting algorithm helpful)
• Barriers to use (qualitative feedback)

Implementation Strategies

Integration into Clinical Workflow

Electronic Health Record Integration

• Clinical decision support (CDS) alerts at key decision points
• Order sets linked to algorithm pathways
• Auto-population of risk scores from EHR data
• Documentation templates following algorithm structure

Point-of-Care Tools

• Pocket cards for quick reference
• Mobile apps with interactive algorithms
• Wall posters in clinical areas
• QR codes linking to full algorithm

Education and Training

• Didactic presentation of algorithm rationale
• Case-based exercises
• Simulation scenarios
• Audit and feedback on adherence

Overcoming Barriers

Common Barriers

• Algorithm complexity (too many decision points)
• Lack of awareness (not disseminated effectively)
• Disagreement with recommendations (perceived as cookbook medicine)
• Competing priorities (time pressure, multiple patients)
• Resource limitations (recommended tests/treatments not available)

Mitigation Strategies

• Simplify algorithms (≤7 decision points per pathway preferred)
• Champion network (local opinion leaders promoting algorithm)
• Customize to local context (allow flexibility for clinical judgment)
• Measure and report outcomes (demonstrate value)
• Provide resources (ensure algorithm-recommended options available)

Algorithm Maintenance and Updates

Version Control

Change Log Documentation

Algorithm: NSCLC First-Line Treatment
Version: 3.2
Effective Date: January 1, 2024
Previous Version: 3.1 (effective July 1, 2023)

Changes in Version 3.2:
1. Added KRAS G12C-mutated pathway (sotorasib, adagrasib)
   - Evidence: FDA approval May 2021/2022
   - Guideline: NCCN v4.2023

2. Updated PD-L1 ≥50% recommendation to include pembrolizumab monotherapy as Option 1
   - Evidence: KEYNOTE-024 5-year follow-up
   - Guideline: NCCN Category 1 preferred

3. Removed crizotinib as preferred ALK inhibitor, moved to alternative
   - Evidence: ALEX, CROWN trials showing superiority of alectinib, lorlatinib
   - Guideline: NCCN/ESMO Category 1 for alectinib as first-line

Reviewed by: Thoracic Oncology Committee
Approved by: Dr. [Name], Medical Director
Next Review Date: July 1, 2024

Trigger for Updates

Mandatory Updates (Within 3 Months)

• FDA approval of new drug for algorithm indication
• Guideline change (NCCN, ASCO, ESMO Category 1 recommendation)
• Safety alert or black box warning added to recommended agent
• Major clinical trial results changing standard of care

Routine Updates (Annually)

• Minor evidence updates
• Optimization based on local performance data
• Formatting or usability improvements
• Addition of new clinical scenarios encountered

Emergency Updates (Within 1 Week)

• Drug shortage requiring alternative pathways
• Drug recall or safety withdrawal
• Outbreak or pandemic requiring modified protocols